Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:7938216.
doi: 10.1155/2017/7938216. Epub 2017 Mar 2.

Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus

Affiliations

Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus

Bernd Stratmann et al. Int J Endocrinol. 2017.

Abstract

Coronary artery disease (CAD) is a common complication of type 2 diabetes mellitus (T2D). This case-control study was done to identify metabolites with different concentrations between T2D patients with and without CAD and to characterise implicated metabolic mechanisms relating to CAD. Fasting serum samples of 57 T2D subjects, 26 with (cases) and 31 without CAD (controls), were targeted for metabolite profiling of 163 metabolites. To assess the association between metabolite levels and CAD, partial least squares (PLS) analysis and multivariate logistic regression analysis with adjustment for CAD risk factors and medications were performed. We observed a separation of cases and controls with two classes of metabolites being significantly associated with CAD, including phosphatidylcholines, and serine. Four metabolites being independent from the common CAD risk factors displaying best separation between cases and controls were further selected. Addition of the metabolite concentrations to risk factor analysis raised the area under the receiver-operating-characteristic curve from 0.72 to 0.88 (p = 0.020), providing improved sensitivity and specificity for CAD classification. Serum phospholipid and serine levels independently discriminate T2D patients with and without CAD. Oxidative stress and reduced antioxidative capacity lead to lower metabolite concentrations probably due to changes in membrane composition and accelerated phospholipid degradation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CAD patients separated from non-CAD subjects. PLS-DA (partial least squares discriminant analysis) results are shown. Subjects with CAD are depicted in yellow and subjects without CAD in blue; medication intake is displayed as insulin therapy (circle) or oral antidiabetic agent intake (triangle); sex differences are highlighted in the size of the symbols: females (larger) and males (smaller).
Figure 2
Figure 2
Boxplots of the four identified CAD-specific metabolites. The continuous horizontal line is the median. The lower boundary of the box represents the 25th percentile, and the other boundary represents the 75th percentile. Whiskers above and below the box represent the 95th and 5th percentile.
Figure 3
Figure 3
Comparison of sensitivity and specificity with and without the four metabolites. ROC curves and measures of model fit (AUC) are presented for (1) model with clinical parameters (sex, age, BMI, HbA1c, diabetes duration, SBP, DBP, antihypertensives, TG, LDL : HDL ratio, lipid-lowering agents, albumin, and eGFR; dashed line) and (2) model combining the four selected metabolites and the clinical model (solid line).

Similar articles

Cited by

References

    1. Lillioja S., Mott D. M., Spraul M., et al. Insulin-resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes-mellitus—prospective studies of Pima-Indians. New England Journal of Medicine. 1993;329(27):1988–1992. doi: 10.1056/NEJM199312303292703. - DOI - PubMed
    1. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocrine Reviews. 1998;19(4):477–490. doi: 10.1210/edrv.19.4.0336. - DOI - PubMed
    1. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine. 2004;141(6):421–431. doi: 10.7326/0003-4819-141-6-200409210-00007. - DOI - PubMed
    1. Stratmann B., Tschoepe D. Sweet heart—contributions of metabolism in the development of heart failure in diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes. 2008;116(Supplement 1):S40–S45. doi: 10.1055/s-2008-1081496. - DOI - PubMed
    1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal. 2014;35(42):2929–2929. doi: 10.1093/eurheartj/ehu378. - DOI - PubMed

LinkOut - more resources